CNS drug design based on principles of blood-brain barrier transport

Journal of Neurochemistry

Volumn 70, Issue 5, 1998, Pages 1781-1792

  Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Antisense oligonucleotides; Biological transport; Blood brain barrier; Drug delivery Drug targeting; Neurotrophins; Small molecules

Indexed keywords

LIPOSOME; NANOPARTICLE; NEUROTROPHIN; OLIGODEOXYNUCLEOTIDE; PEPTIDE NUCLEIC ACID;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN PROTECTION; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG TRANSPORT; HUMAN; HYDROGEN BOND; LIPID SOLUBILITY; LIPID TRANSPORT; MOLECULAR MODEL; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0031959341     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.70051781.x     Document Type: Short Survey

References (102)

1. Aasmundstad T. A., Morg J., and Paleness R. E. (1995) Distribution of morphine-6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling. J. Pharmacol. Exp. Ther. 275, 435-441.
2. 14C]thymidine in mice. J. Pharmacol. Exp. Ther. 257, 479-486.
3. Alyautdin R. N., Petrov V. E., Langer K., Berthold A., Kharkevich D. A., and Kreuter J. (1997) Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 14, 325-328.
4. Begley D. J. (1996) The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J. Pharm. Pharmacol. 48, 136-146.
5. Beltinger C., Saragovi H. U., Smith R. M., LeSauteur L., Shah N., DeDionisio L., Christensen L., Raible A., Jarett L., and Gewirtz A. M. (1995) Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95, 1814-1823.
6. Bickel U., Yoshikawa T., Landaw E. M., Faull K. F., and Pardridge W. M. (1993) Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Natl. Acad. Sci. USA 90, 2618-2622.
7. Bickel U., Kang Y.-S., Yoshikawa T., and Pardridge W. M. (1994) In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate within brain capillary endothelium. J. Histochem. Cytochem. 42, 1493-1497.
8. Bickel U., Schumacher O., Kang Y.-S., and Voigt K. (1996) Poor permeability of morphine-3-glucuronide and morphine-6-glucuronide through the blood-brain barrier in the rat. J. Pharmacol. Exp. Ther. 278, 107-113.
9. Blanco-Príeto M. J., Durieux C., Daugé V., Fattal E., Couvreur P., and Roques B. P. (1996) Slow delivery of the selective cholecystokinin agonist pBC 264 into the rat nucleus accumbens u sing microspheres. J. Neurochem. 67, 2417-2424.
10. Brightman M. W., Reese T. S., and Feder N. (1970) Assessment with the electron-microscope of the permeability to peroxidase of cerebral endothelium and epithelium in mice and sharks, in Capillary Permeability (Crone C. and Lassen N. A., eds), p. 463. Munksgaard, Copenhagen.
11. Broadwell R. D., Baker-Cairns B. J., Friden P. M., Oliver C., and Villegas J. C. (1996) Transcytosis of protein through the mammalian cerebral epithelium and endothelium. Exp. Neurol. 142, 47-65.
12. Brown D. A., Kang S.-H., Gryaznov S. M., DeDionisio L., Heidenreich O., Sullivan S., Xu X., and Nerenberg M. I. (1994) Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269, 26801-26805.
13. Bundgaard H. and Moss J. (1990) Prodrugs of peptides. 6. Bioreversible derivatives of thyrotropin-releasing hormone (TRH) with increased lipophilicity and resistance to cleavage by the TRH-specific serum enzyme. Pharm. Res. 7, 885-892.
14. Cordon-Cardo C., O'Brien J. P., Casals D., Rittman-Grauer L., Biedler J. L., Melamed M. R., and Bertino J. R. (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86, 695-698.
15. Cornford E. M. and Oldendorf W. H. (1975) Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim. Biophys. Acta 394, 211-219.
16. Cornford E. M., Diep C. P., and Pardridge W. M. (1985) Blood-brain barrier transport of valproic acid. J. Neurochem. 44, 1541-1550.
17. Crabbe J. C., Belknap J. K., and Buck K. J. (1994) Genetic animal models of alcohol and drug abuse. Science 264, 1715-1723.
18. Deguchi Y., Inabe K., Tomiyasu K., Nozawa K., Yamada S., and Kimura R. (1995) Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. Pharm. Res. 12, 1828-1844.
19. Dehouck B., Fenart L., Dehouck M.-P., Pierce A., Torpier G., and Cecchelli R. (1997) A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 138, 877-899.
20. Descamps L., Dehouck M.-P., Torpier G., and Cecchelli R. (1996) Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells. Am. J. Physiol. 270, H1149-H1158.
21. Diamond J. M. and Wright E. M. (1969) Molecular forces governing non-electrolyte permeation through cell membranes. Proc. R. Soc. Lond. [Biol.] 172, 273-316.
22. Dohrmann G. (1970) The choroid plexus: a historical review. Brain Res. 18, 197-218.
23. Duffy K. R. and Padridge W. M. (1987) Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res. 420, 32-38.
24. Dykstra K. H., Arya A., Arriola D. M., Bungay P. M., Morrison P. F., and Dedrick R. L. (1993) Microdialysis study of zidovudine (AZT) transport in rat brain. J. Pharmacol. Exp. Ther. 267, 1227-1236.
25. Eibl H. (1984) Phospholipids as functional constituents of biomembranes. Angew. Chem. Int. Ed. Engl. 23, 257-271.
26. 50 nanoparticles by complexation with structured oligopeptides. Drug Delivery 3, 187-195.
27. Fennewald S. M. and Rando R. F. (1995) Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J. Biol. Chem. 270, 21718-21721.
28. Fenstermacher J. and Kaye T. (1988) Drug "diffusion" within the brain. Ann. NY Acad. Sci. 531, 29-39.
29. Fishman J. B., Rubin J. B., Handrahan J. V., Connor J. R., and Fine R. E. (1987) Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 18, 299-304.
30. Fishman R. A. (1980) Cerebrospinal Fluid in Diseases of the Nervous System. W. B. Saunders Company, Philadelphia.
31. Friden P. M., Walus L. R., Watson P., Doctrow S. R., Kozarich J. W. Backman C., Bergman H., Hoffer B., Blood F., and Granholm A.-C. (1993) Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 259, 373-377.
32. Galinsky R. E., Hoesterey B. L., and Anderson B. D. (1990) Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. Life Sci. 47, 781-788.
33. Gao W.-Y., Han F.-S., Storm C., Egan W., and Cheng Y.-C. (1992) Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol. Pharmacol. 41, 223-229.
34. Gennuso R., Spigelman M. K., Chinol M., Zappulla R. A., Nieves J., Vallabhajosula S., Paciucci P. A., Goldsmith S. J., and Holland J. F. (1993) Effect of blood-brain barrier and blood-tumor barrier modification on central nervous system liposomal uptake. Cancer Invest. 11, 118-128.
35. 1-40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport 7, 2607-2611.
36. 3) receptors within the blood-brain barrier prevents cisplatin-induced emesis in dogs. J. Pharmacol. Exp. Ther. 273, 695-701.
37. Gref R., Minamitake Y., Peracchia M. T., Trubetskoy V., Torchilin V., and Langer R. (1994) Biodegradable long-circulating polymeric nanospheres. Science 263, 1600-1603.
38. Guvakova M. A., Yakubov L. A., Vlodavsky I., Tonkinson J. L., and Stein C. A. (1995) Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270, 2620-2627.
39. Hefti F. (1997) Pharmacology of neurotrophic factors. Annu. Rev. Pharmacol. Toxicol. 37, 239-267.
40. Higuchi T. and Davis S. S. (1970) Thermodynamic analysis of structure-activity relationships of drugs: prediction of optimal structure. J. Pharm. Sci. 59, 1376-1383.
41. Hingson D. J. and Diamond J. M. (1972) Comparison of nonelectrolyte permeability patterns in several epithelia. J. Membr. Biol. 10, 93-135.
42. Hirohashi T., Terasaki T., Shigetoshi M., and Sugiyama Y. (1997) In vivo and in vitro evidence for nonrestricted transport of 2′,7′-bis(2-carboxyethyl)-5(6)-carboxyfluorescein tetraacetoxymethyl ester at the blood-brain barrier. J. Pharmacol. Exp. Ther. 280, 813-819.
43. Huwyler J., Wu D., and Pardridge W. M. (1996) Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA 93, 14164-14169.
44. Huwyler J., Yang J., and Pardridge W. M. (1997) Targeted delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J. Pharmacol. Exp. Ther. 282, 1541-1546.
45. Jain R. K. (1990) Tumor physiology and antibody delivery. Front. Radiat. Ther. Oncol. 24, 32-46.
46. Jette L., Tetu B., Beliveau R. (1993) High levels of P-glycoprotein detected in isolated brain capillaries. Biochim. Biophys. Acta 1150, 147-154.
47. Kim S., Scheerer S., Geyer M. A., and Howell S. B. (1990) Direct cerebrospinal fluid delivery of an antiretroviral agent using multivesicular liposomes. J. Infect. Dis 162, 750-752.
48. Kuntz I. D. (1992) Structure-based strategies for drug design and discovery. Science 257, 1078-1082.
49. Levin V. A. (1980) Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23, 682-684.
50. Lin J. H., Chen I.-W., and Lin T.-H. (1994) Blood-brain barrier permeability and in vivo activity of partial agonists of benzodiazepine receptor: a study of L-663,581 and its metabolites in rats. J. Pharmacol. Exp. Ther. 271, 1197-1202.
51. Maggio J. E., Stimson E. R., Ghilardi J. R., Allen C. J., Dahl C. E., Whitcomb D. C., Vigna S. R., Vinters H. V., Labenski M. E., and Mantyh P. W. (1992) Reversible in vitro growth of Alzheimer disease β-amyloid plaques by deposition of labeled amyloid peptide. Proc. Natl. Acad. Sci. USA 89, 5462-5466.
52. Mak M., Fung L., Strasser J. F., and Saltzman W. M. (1995) Distribution of drugs following controlled delivery to the brain interstitium. J. Neurooncol. 26, 91-102.
53. Møllegaard N. E., Buchardt O., Egholm M., and Nielsen P. E. (1994) Peptide nucleic acid·DNA strand displacement loops as artificial transcription promoters. Proc. Natl. Acad. Sci. USA 91, 3892-3895.
54. Morgan M. E., Singhal D., and Anderson B. D. (1996) Quantitative assessment of blood-brain barrier damage during microdialysis. J. Pharmacol. Exp. Ther. 277, 1167-1176.
55. Mouritsen O. G. and Jørgensen K. (1997) Small-scale lipid-membrane structure: simulation versus experiment. Curr. Opin. Struct. Biol. 7, 518-527.
56. Nadal A., Fruentes E., Pastor J., and McNaughton P. A. (1995) Plasma albumin is a potent trigger of calcium signals and DNA synthesis in astrocytes. Proc. Natl. Acad. Sci. USA 92, 1426-1430.
57. Neuwelt E. A. and Rapoport S. I. (1984) Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Fed. Proc. 43, 214-219.
58. Oldendorf W. H. (1974) Blood-brain barrier permeability to drugs. Annu. Rev. Pharmacol. 14, 239-248.
59. Pardridge W. M. (1991) Peptide Drug Delivery to the Brain, pp. 1-357. Raven Press, New York.
60. Pardridge W. M. (1997) Drug delivery to the brain. J. Cereb. Blood Flow Metab. 17, 713-731.
61. Pardridge W. M. and Mietus L. J. (1979) Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. J. Clin. Invest. 64, 145-154.
62. Pardridge W. M. and Oldendorf W. H. (1977) Transport of metabolic substrates through the blood-brain barrier. J. Neurochem. 28, 5-12.
63. Pardridge W. M., Boado R. J., and Farrell C. R. (1990a) Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization. J. Biol. Chem. 265, 18035-18040.
64. Pardridge W. M., Triguero D., Yang J., and Cancilla P. A. (1990b) Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J. Pharmacol. Exp. Ther. 253, 884-891.
65. Pardridge W. M., Kang Y.-S., and Buciak J. L. (1994) Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pharm. Res. 11, 738-746.
66. Pardridge W. M., Boado R. J., and Kang Y.-S. (1995a) Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. USA 92, 5592-5596.
67. Pardridge W. M., Kang Y.-S., Buciak J. L., and Yang J. (1995b) Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res. 12, 807-816.
68. Pardridge W. M., Golden P. L., Kang Y.-S., and Bickel U. (1997) Brain microvascular and astrocyte localization of P-glycoprotein. J. Neurochem. 68, 1278-1285.
69. Polt R., Porreca F., Szabo L. Z., Bilsky E. J., Davis P., Abbruscato T. J., Davis T. P., Horvath R., Yamamura H. I., and Hruby V. J. (1994) Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc. Natl. Acad. Sci. USA 91, 7114-7118.
70. Roberts R. L., Fine R. E., and Sandra A. (1993) Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J. Cell Sci. 104, 521-532.
71. Rosenberg M. B., Hawrot E., and Breakefield X. O. (1986) Receptor binding activities of biotinylated derivatives of β-nerve growth factor. J. Neurochem. 46, 641-648.
72. 1-40/vector complex. Proc. Natl. Acad. Sci. USA 92, 10227-10231.
73. Sakamoto A. and Ido T. (1993) Liposome targeting to rat brain: effect of osmotic opening of the blood-brain barrier. Brain Res. 629, 171-175.
74. Sakane T. and Pardridge W. M. (1997) Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm. Res. 14, 1085-1091.
75. Sakane T., Akizuki M., Yamashita S., Nadai T., Hashida M., and Sezaki H. (1991) The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem. Pharm. Bull. (Tokyo) 39, 2456-2458.
76. Salahuddin T. S., Johansson B. B., Kalimo H., and Olsson Y. (1988) Structural changes in the rat brain after carotid infusions of hyperosmolar solutions. An electron microscopic study. Acta Neuropathol. 77, 5-13.
77. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45, 932-943.
78. Schackert G., Fan D., Nayar R., and Fidler I. J. (1989) Arrest and retention of multilamellar liposomes in the brain of normal mice or mice bearing experimental brain metastases. Sel. Cancer Ther. 5, 73-79.
79. Shin S.-U., Wu D., Ramanathan R., Pardridge W. M., and Morrison S. L. (1997) Functional and pharmacokinetic properties of antibody/avidin fusion proteins. J. Immunol. 158, 4797-4804.
80. 2-macroglobulin and the binding is inhibited by heparin. J. Biol. Chem. 268, 7685-7691.
81. Spector R. and Berlinger W. G. (1982) Localization and mechanism of thymidine transport in the central nervous system. J. Neurochem. 39, 837-841.
82. Spector R. and Huntoon S. (1984) Specificity and sodium dependence of the active nucleoside transport system in choroid plexus. J. Neurochem. 42, 1048-1052.
83. Stein W. D. (1967) The molecular basis of diffusion across cell membranes, in The Movement of Molecules Across Cell Membranes, pp. 65-125. Academic Press, New York.
84. Suzuki H., Terasaki T., and Sugiyama Y. (1997) Role of efflux transport across the blood-brain barrier and blood cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system. Adv. Drug Del. Rev. 25, 257-285.
85. Takasawa K., Terasaki T., Suzuki H., and Sugiyama Y. (1997) In vivo evidence for carrier-mediated efflux transport of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. J. Pharmacol. Exp. Ther. 281, 369-375.
86. Tamai I. and Tsuji A. (1996) Drug delivery through the blood-brain barrier. Adv. Drug Del. Rev. 19, 401-424.
87. Terasaki T. and Pardridge W. M. (1988) Restricted transport of AZT and dideoxynucleosides through the blood-brain barrier. J. Infect. Dis. 158, 630-632.
88. Thorne R. G., Emory C. R., Ala T. A., and Frey W. H. II (1995) Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res. 692, 278-282.
89. Träuble H. (1971) The movement of molecules across lipid membranes: a molecular theory. J. Membr. Biol. 4, 193-208.
90. Vorbrodt A. W. (1989) Ultracytochemical characterization of anionic sites in the wall of brain capillaries. J. Neurocytol. 18, 359-368.
91. Wade L. A. and Katzman R. (1975) Rat brain regional uptake and decarboxylation of L-dopa following carotid injection. Am. J. Physiol. 228, 352-359.
92. Wahlestedt C. (1994) Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol. Sci. 15, 42-46.
93. White F. P., Dutton G. R., and Norenberg M. D. (1981) Microvessels isolated from rat brain: localization of astrocyte processes by immunohistochemical techniques. J. Neurochem. 36, 328-332.
94. Whitesell L., Geselowitz D., Chavany C., Fahmy B., Walbridge S., Alger J. R., and Neckers L. M. (1993) Stability, clearance, and disposition of intraventricularly administered oligodeoxy-nucleotides: implications for therapeutic application within the central nervous system. Proc. Natl. Acad. Sci. USA 90, 4665-4669.
95. Wojcik W. J., Swoveland P., Zhang X., and Vanguri P. (1996) Chronic intrathecal infusion of phosphorothioate or phosphodiester antisense oligonucleotides against cytokine responsive gene-2/IP-10 in experimental allergic encephalomyelitis of Lewis rat. J. Pharmacol Exp. Ther. 278, 404-410.
96. Wu D. and Pardridge W. M. (1996) CNS pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analogue coupled to a blood-brain barrier drug delivery system. J. Pharmacol. Exp. Ther. 279, 77-83.
97. 3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J. Pharmacol. Exp. Ther. 276, 206-211.
98. Wu D., Kang Y.-S., Bickel U., and Pardridge W. M. (1997a) Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared to morphine. Drug Metab. Dispos. 25, 768-771.
99. Wu D., Yang J., and Pardridge W. M. (1997b) Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Invest. 100, 1804-1812.
100. Xiang T.-X. and Anderson B. D. (1994) The relationship between permeant size and permeability in lipid bilayer membranes. J. Membr. Biol. 140, 111-122.
101. Yang W. X., Terasaki T., Shiroki K., Ohka S., Aoki J., Tanabe S., Nomura T., Terada E., Sugiyama Y., and Nomoto A. (1997) Efficient delivery of circulating poliovirus to the central nervous system independently of poliovirus receptor. Virology 229, 421-428.
102. Yarchoan R. and Broder S. (1987) Development of antiretroviral therapy for acquired immunodeficiency syndrome and related disorders. N. Engl. J. Med. 316, 557-564.